Saqib Islam
Chief Executive Officer at SPRINGWORKS THERAPEUTICS, INC.
Net worth: 35 M $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Stephen P. Squinto | M | 67 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 31 years |
Daniel Lynch | M | 65 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 8 years |
Edgar Cale | M | 60 | 5 years | |
Yung-Shin Alexander Kung | M | - |
Credit Suisse Asset Management LLC
Credit Suisse Asset Management LLC Investment ManagersFinance Founded in 1999, Credit Suisse Asset Management LLC (CSAM) is a registered investment advisor headquartered in New York City. The firm is an indirect wholly-owned subsidiary of Credit Suisse Group AG (NYSE: CS), a publicly owned foreign bank holding company based in Switzerland. | 15 years |
Richard Lowenthal | M | 58 | 9 years | |
William Chou | M | 51 | 2 years | |
Daniel Simkowitz | M | 57 | 24 years | |
Jeffrey Schwartz | M | 45 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 7 years |
Maxine Gowen | M | 66 | 3 years | |
Eric Grossman | M | 57 | 18 years | |
Stéphane Bancel | M | 51 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | - |
Michael Rongetti | M | - |
Credit Suisse Asset Management LLC
Credit Suisse Asset Management LLC Investment ManagersFinance Founded in 1999, Credit Suisse Asset Management LLC (CSAM) is a registered investment advisor headquartered in New York City. The firm is an indirect wholly-owned subsidiary of Credit Suisse Group AG (NYSE: CS), a publicly owned foreign bank holding company based in Switzerland. | 12 years |
Shannon Klinger | M | 53 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | - |
James Gorman | M | 65 | 18 years | |
Freda Lewis-Hall | M | 69 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 7 years |
Alan Fuhrman | M | 67 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 5 years |
Deval Patrick | M | 67 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 3 years |
Kim Diamond | F | - | 6 years | |
Robert Bell | M | - | 9 years | |
Sarina Tanimoto | M | 55 | 9 years | |
Kathleen Borthwick | F | 48 | 3 years | |
Derrell Porter | M | 53 | 3 years | |
James M. Wilson | M | - | 7 years | |
Frederick Pollock | M | 44 | 18 years | |
Herschel Weinstein | M | 68 | 4 years | |
Sandipkumar S. Kapadia | M | 54 | 5 years | |
Brian Dorsey | M | 55 | 6 years | |
Badreddin Edris | M | 37 | 6 years | |
Rajeev Dadoo | M | 54 | 3 years | |
Stephen Hoge | M | 48 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | - |
Justin Chakma | M | 35 | 5 years | |
Peter Kolchinsky | M | 47 | 3 years | |
Peter Thompson | M | 64 | 2 years | |
Pratik Shah | M | 54 | 8 years | |
Phillip Schneider | M | 67 | 5 years | |
Alexander Fitzpatrick | M | 57 | 2 years | |
Julie Hambleton | M | 66 | 4 years | |
Michael Kelly | M | 59 | 5 years | |
Carlos Alban | M | 61 | 2 years | |
Stuart M. Henderson | M | - | 3 years | |
Athena Countouriotis | M | 52 | 4 years | |
James Cassidy | M | 65 | 3 years | |
Mandell Crawley | M | 48 | 20 years | |
Daniel Pichl | M | 41 | 4 years | |
Jack Szostak | M | - |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | - |
Bhavesh Ashar | M | 58 | 3 years | |
Eric Karas | M | 52 | 2 years | |
Brenton Saunders | M | 56 | 3 years | |
Daniel Relovsky | M | - | 2 years | |
Frank Ducomble | M | - | 18 years | |
Michael Nofi | M | 53 | 5 years | |
Marcello Damiani | M | 54 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | - |
Lorence Kim | M | 49 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | 10 years |
Kathleen Scott | F | 55 | 2 years | |
Laura Shawver | M | 66 | 2 years | |
Peter Hutt | M | 89 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | 12 years |
Frank Perier | M | 64 | 5 years | |
Sarah Marshall | F | - | 10 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bruce Goldsmith | M | 58 | 2 years | |
David Brennan | M | 70 | 7 years | |
Joseph A. Madri | M | 80 | 22 years | |
Michael Altman | M | 42 | 1 years | |
Robert Scott | M | 78 | 2 years | |
Jim Kasinger | M | 52 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | 3 years |
Thomas R. Nides | M | 63 | 5 years | |
Jonathan Pruzan | M | 55 | 18 years | |
Lara Sullivan | M | 51 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 1 years |
Adam Stone | M | 44 | 1 years | |
Mark Day | M | 52 | 2 years | |
Konstantin Poukalov | M | 40 | 1 years | |
Liam Ratcliffe | M | 60 | 3 years | |
Israel Ruiz | M | 52 | - | |
Michael V. Greco | M | 53 | 1 years | |
Jens Renstrup | M | 59 | 6 years | |
L. Smith | M | 57 | 7 years | |
Lisa Lejuwaan | F | - | - | |
Juan Andres | M | 59 | 6 years | |
Scott Peters | M | - | 8 years | |
Ruth Porat | F | 66 | 12 years | |
Nadav Zohar | M | 59 | 7 years | |
Felix Baker | M | 55 | 6 years | |
John Carl Hahn | M | 65 | 11 years | |
Joseph Edelman | M | 67 | 1 years | |
Larry L. Mathis | M | 80 | 10 years | |
Bradley Campbell | M | 48 | - | |
Michael Kamarck | M | 73 | 1 years | |
Jonathan Leff | M | 55 | 5 years | |
M. Burns | F | 66 | 4 years | |
Carl Gordon | M | 59 | 2 years | |
Max E. Link | M | 84 | 22 years | |
Jordan Low | M | - |
Credit Suisse Asset Management LLC
Credit Suisse Asset Management LLC Investment ManagersFinance Founded in 1999, Credit Suisse Asset Management LLC (CSAM) is a registered investment advisor headquartered in New York City. The firm is an indirect wholly-owned subsidiary of Credit Suisse Group AG (NYSE: CS), a publicly owned foreign bank holding company based in Switzerland. | 4 years |
Gary W. Parr | M | 67 | 9 years | |
Eileen Murray | F | 66 | 2 years | |
William Keller | M | 75 | 6 years | |
Moncef Slaoui | M | 64 | 3 years | |
Jack Mollen | M | 73 | 7 years | |
Thomas Woiwode | M | 52 | 5 years | |
Christopher Coughlin | M | 71 | 7 years | |
Klaus Svendsen | M | - | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Saqib Islam
- Personal Network